B.Riley Financial has downgraded Capricor Therapeutics (NASDAQ: CAPR) from Buy to Neutral, citing worries raised by newly released FDA briefing documents. The documents, prepared ahead of an advisory committee meeting, flagged potential safety and efficacy questions regarding Capricor's lead experimental therapy for Duchenne muscular dystrophy. The downgrade sent Capricor shares down sharply in pre-market trading, with the stock falling more than 12% in early New York trade.
The FDA briefing materials, published late last week, highlighted uncertainties in the clinical data package for Capricor's cell therapy candidate, including the durability of treatment effects and the size of the pivotal trial. While not a final decision, such documents often signal the agency's preliminary concerns and can influence advisory panel voting. B.Riley analysts noted that the risks now appear elevated enough to warrant a more cautious stance, removing their previous price target of $18 per share.
For UK investors, the downgrade underscores the volatility inherent in small-cap biotech stocks, which can swing sharply on regulatory news. There is no direct FTSE 100 exposure to Capricor, but the broader biotech sector — including UK-listed firms such as Oxford Nanopore Technologies and Abcam — can be affected by shifts in risk appetite. The iShares Nasdaq Biotechnology ETF (IBB), popular among UK retail investors, fell 0.8% in sympathy with Capricor's decline.
Analysts at Peel Hunt, commenting on the sector, said the episode highlights the high-stakes nature of FDA advisory meetings, where briefing documents can 'make or break' investor confidence weeks before a formal decision. They added that UK pension funds with exposure to US healthcare funds should brace for potential near-term volatility, though the fundamental outlook for the broader biotech sector remains intact.
Capricor has not yet issued a formal response to the B.Riley downgrade. The FDA advisory committee meeting is expected to take place in the coming weeks, with a final regulatory decision on the therapy anticipated later this year. For now, investors are advised to monitor the advisory panel's vote closely, as it often sets the tone for the agency's ultimate verdict.